JNJ•benzinga•
Johnson & Johnson Announces Results For The Gold Standard Endpoint In Cancer Treatment Of Overall Survival From The Phase 3 MARIPOSA Study; Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 26, 2025 by benzinga